Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Common Equity (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Common Equity for 4 consecutive years, with $683.4 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 9.78% to $683.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $683.4 million through Dec 2025, down 9.78% year-over-year, with the annual reading at $683.4 million for FY2025, 9.78% down from the prior year.
  • Common Equity hit $683.4 million in Q4 2025 for NewAmsterdam Pharma, down from $728.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $778.5 million in Q2 2025 to a low of $288.4 million in Q4 2023.
  • Historically, Common Equity has averaged $522.3 million across 4 years, with a median of $411.8 million in 2024.
  • Biggest five-year swings in Common Equity: crashed 41.66% in 2023 and later skyrocketed 162.66% in 2024.
  • Year by year, Common Equity stood at $494.3 million in 2022, then plummeted by 41.66% to $288.4 million in 2023, then surged by 162.66% to $757.5 million in 2024, then fell by 9.78% to $683.4 million in 2025.
  • Business Quant data shows Common Equity for NAMS at $683.4 million in Q4 2025, $728.1 million in Q3 2025, and $778.5 million in Q2 2025.